Gilead Sciences Valuation

Gilead Sciences Inc -- USA Stock  

USD 79.51  0.23  0.29%

Gilead Sciences Inc retains regular Real Value of $86.435 per share. The prevalent price of the corporation is $79.51. At this time the corporation appears to be under valued. Macroaxis calculates value of Gilead Sciences Inc from evaluating the corporation fundamentals such as Current Valuation of 111.85B, Return On Asset of 14.15% and Return On Equity of 23.30% as well as inspecting its technical indicators and Probability Of Bankruptcy. In general, we encourage to acquire undervalued assets and to sell overvalued assets since at some point stocks prices and their ongoing real values will come together.

Gilead Science took a bad hit when their bet on a medical trial failed.  Subsequently, their stock price has come down considerably. But, the company is still profitable and is very focused on growth ahead.  Also, market forces should easily push the stock price higher than where it is when looked at from a price-to-earnings ratio.  For that matter, by any matrix, the stock is cheap and should go higher.  

Valuation Drivers Correlation

Selected Gilead Sciences Inc Valuation Data Over Time

Net Income Per Employee    Enterprise Value    Market Capitalization    
 Time Horizon     30 Days    Login   to change
Gilead Sciences Inc is one of the top stocks in price to book category among related companies. It is rated # 3 in price to earning category among related companies reporting about  4.45  of Price to Earning per Price to Book.
Under Valued
March 18, 2018
Market Value
Downside upside
Real Value
Target Price Odds
 Above  Below  
Upside upside
Gilead Sciences is not too risky asset. Calculation of real value of Gilead Sciences Inc is based on 1 month time horizon. Increasing Gilead Sciences Inc time horizon generally increases accuracy of value calculation and significantly improves predictive power of the methodology used.


Gilead Sciences Analyst Recommendations
Target PriceAdvice# of Analysts
Gilead Sciences Inc current and past analyst recommendations published by number of research institutions as well as average analyst consensus
Gilead Sciences Analyst Advice  

Tax Efficiency

Gilead Sciences Inc Tax Efficiency History

Tax Efficiency

Market Capitalization

Gilead Sciences Market Capitalization Analysis
Gilead Sciences Inc is rated # 2 in market capitalization category among related companies. Market capitalization of Pharmaceuticals And Biosciences industry is currently estimated at about 321.77 Billion. Gilead Sciences totals roughly 104.46 Billion in market capitalization claiming about 32% of equities listed under Pharmaceuticals And Biosciences industry.
Capitalization  Revenue  Total debt  Workforce  Valuation


Gilead Sciences Inc Revenue
Based on latest financial disclosure Gilead Sciences Inc reported 26.11 B of revenue. This is 301.7% higher than that of the Healthcare sector, and significantly higher than that of Pharmaceuticals And Biosciences industry, The Revenue for all stocks is 165.17% lower than the firm.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can includes product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.